Lilly licenses Lycia’s protein degrader tech

Abstract

Eli Lilly and Company will license Lycia Therapeutics’ lysosome-based protein degrader technology for $35 million and up to $1.6 billion in future payments. With its lysosomal targeting chimera (LYTAC) technology, Lycia aims to create small molecules and antibodies targeting difficult-to-drug proteins, including cell surface receptors and secreted proteins. The technology was developed by chemical biologist Carolyn Bertozzi at Stanford University. She has resigned her board seat at Lilly.